Blog | Veristat Insightful Perspectives

December 2019 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in December 2019.

November 2019 Updates from FDA 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in November 2019.

An Interview with Kevin Hennegan, Senior Regulatory Strategist, Veristat

Understanding the Various Considerations for EDC Selection

An Interview with  Kathleen Boruchowski, Director of Data Management, Veristat 

October 2019 Updates from FDA 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in October 2019.

Four Years and Counting....

Veristat is proud to have participated in the Leukemia & Lymphoma Society’s Light The Night Walk for the fourth year in a row. This year, for the first time, Veristat participated in two walk locations: Boston and Toronto!

An Interview with Dunya Botetzayas, RN, Senior Director of Clinical Monitoring at Veristat

September 2019 Updates from FDA 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in September 2019.

An Interview with Dr. Deepen Patel, Vice President of Medical Affairs at Veristat

August 2019 Updates from FDA 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in August 2019.